{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:19:23Z","timestamp":1790626763766,"version":"4.1.0"},"reference-count":48,"publisher":"Spandidos Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.3892\/mco.2014.279","type":"journal-article","created":{"date-parts":[[2014,4,16]],"date-time":"2014-04-16T03:23:13Z","timestamp":1397618593000},"page":"559-566","source":"Crossref","is-referenced-by-count":48,"title":["Comparison of serum human epididymis protein 4 and carbohydrate antigen 125 as markers in ovarian cancer: A meta-analysis"],"prefix":"10.3892","volume":"2","author":[{"given":"SHUAI","family":"ZHEN","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LI-HONG","family":"BIAN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LI-LI","family":"CHANG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XIN","family":"GAO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2014,4,16]]},"reference":[{"key":"key20180107150713_b1-mco-02-04-0559","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3322\/caac.20121","article-title":"Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths","volume":"61","author":"Siegel","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"key20180107150713_b2-mco-02-04-0559","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1097\/IGC.0b013e31821a3726","article-title":"Human epididymis protein 4 (HE4) as a serum tumor biomarker in patients with ovarian carcinoma","volume":"21","author":"Chang","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"key20180107150713_b3-mco-02-04-0559","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/j.ygyno.2006.08.022","article-title":"Summary and discussion of session recommendations","volume":"103","author":"Fountain","year":"2006","journal-title":"Gynecol Oncol"},{"key":"key20180107150713_b4-mco-02-04-0559","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/1096-9098(200012)75:4<264::AID-JSO7>3.0.CO;2-Q","article-title":"Benign conditions associated with raised serum CA-125 concentration","volume":"75","author":"Buamah","year":"2000","journal-title":"J Surg Oncol"},{"key":"key20180107150713_b5-mco-02-04-0559","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1200\/JCO.2008.19.2484","article-title":"Development of a multimarker assay for early detection of ovarian cancer","volume":"28","author":"Yurkovetsky","year":"2010","journal-title":"J Clin Oncol"},{"key":"key20180107150713_b6-mco-02-04-0559","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1186\/1471-2407-11-499","article-title":"Improved blood tests for cancer screening: general or specific?","volume":"11","author":"Cree","year":"2011","journal-title":"BMC Cancer"},{"key":"key20180107150713_b7-mco-02-04-0559","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1158\/0008-5472.CAN-04-3924","article-title":"Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas","volume":"65","author":"Drapkin","year":"2005","journal-title":"Cancer Res"},{"key":"key20180107150713_b8-mco-02-04-0559","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/modpathol.3800612","article-title":"Comprehensive analysis of HE4 expression in normal and malignant human tissues","volume":"19","author":"Galgano","year":"2006","journal-title":"Mod Pathol"},{"key":"key20180107150713_b9-mco-02-04-0559","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3802\/jgo.2011.22.4.244","article-title":"Evaluation of ovarian cancer biomarkers HE4 and CA-125 in women presenting with a suspicious cystic ovarian mass","volume":"22","author":"Partheen","year":"2011","journal-title":"J Gynecol Oncol"},{"key":"key20180107150713_b10-mco-02-04-0559","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1186\/1471-2407-12-258","article-title":"Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and CA125 in predicting epithelial ovarian cancer: a meta-analysis","volume":"12","author":"Li","year":"2012","journal-title":"BMC Cancer"},{"key":"key20180107150713_b11-mco-02-04-0559","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"key20180107150713_b12-mco-02-04-0559","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"key20180107150713_b13-mco-02-04-0559","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann Intern Med"},{"key":"key20180107150713_b14-mco-02-04-0559","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1373\/49.1.1","article-title":"Standards for Reporting of Diagnostic Accuracy: Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic Accuracy","volume":"49","author":"Bossuyt","year":"2003","journal-title":"Clin Chem"},{"key":"key20180107150713_b15-mco-02-04-0559","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-2-9","article-title":"Conducting systematic reviews of diagnostic studies: didactic guidelines","volume":"2","author":"Devill\u00e9","year":"2002","journal-title":"BMC Med Res Methodol"},{"key":"key20180107150713_b16-mco-02-04-0559","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"key20180107150713_b17-mco-02-04-0559","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1093\/jnci\/djn326","article-title":"Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design","volume":"100","author":"Pepe","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"key20180107150713_b18-mco-02-04-0559","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S0895-4356(03)00177-X","article-title":"The diagnostic odds ratio: a single indicator of test performance","volume":"56","author":"Glas","year":"2003","journal-title":"J Clin Epidemiol"},{"key":"key20180107150713_b19-mco-02-04-0559","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1002\/sim.1099","article-title":"Properties of the summary receiver operating characteristic (SROC) curve for diagnostic test data","volume":"21","author":"Walter","year":"2002","journal-title":"Stat Med"},{"key":"key20180107150713_b20-mco-02-04-0559","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1037\/1082-989X.11.2.193","article-title":"Assessing heterogeneity in meta-analysis: Q statistic or I2index?","volume":"11","author":"Huedo-Medina","year":"2006","journal-title":"Psychol Methods"},{"key":"key20180107150713_b21-mco-02-04-0559","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta9120","article-title":"A methodological review of how heterogeneity has been examined in systematic reviews of diagnostic test accuracy","volume":"9","author":"Dinnes","year":"2005","journal-title":"Health Technol Assess"},{"key":"key20180107150713_b22-mco-02-04-0559","first-page":"111","article-title":"HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses","volume":"11","author":"Abdel-Azeez","year":"2010","journal-title":"Asian Pac J Cancer Prev"},{"key":"key20180107150713_b23-mco-02-04-0559","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s13277-009-0015-y","article-title":"HE4: a new potential early biomarker for the recurrence of ovarian cancer","volume":"31","author":"Anastasi","year":"2010","journal-title":"Tumor Biol"},{"key":"key20180107150713_b24-mco-02-04-0559","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.ygyno.2009.10.087","article-title":"Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer","volume":"116","author":"Andersen","year":"2010","journal-title":"Gynecol Oncol"},{"key":"key20180107150713_b25-mco-02-04-0559","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1038\/sj.bjc.6606092","article-title":"HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm","volume":"104","author":"Van Gorp","year":"2011","journal-title":"Br J Cancer"},{"key":"key20180107150713_b26-mco-02-04-0559","doi-asserted-by":"crossref","first-page":"358.e1","DOI":"10.1016\/j.ajog.2011.05.017","article-title":"Human epididymis protein 4 offers superior specificity in the differentiation of benign and malignant adnexal masses in premenopausal women","volume":"205","author":"Holcomb","year":"2011","journal-title":"Am J Obstet Gynecol"},{"key":"key20180107150713_b27-mco-02-04-0559","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ygyno.2011.02.022","article-title":"No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting","volume":"121","author":"Jacob","year":"2011","journal-title":"Gynecol Oncol"},{"key":"key20180107150713_b28-mco-02-04-0559","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1515\/CCLM.2011.075","article-title":"The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful?","volume":"49","author":"Montagnana","year":"2011","journal-title":"Clin Chem Lab Med"},{"key":"key20180107150713_b29-mco-02-04-0559","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ygyno.2007.10.017","article-title":"The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass","volume":"108","author":"Moore","year":"2008","journal-title":"Gynecol Oncol"},{"key":"key20180107150713_b30-mco-02-04-0559","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.ygyno.2010.02.005","article-title":"Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass","volume":"117","author":"Nolen","year":"2010","journal-title":"Gynecol Oncol"},{"key":"key20180107150713_b31-mco-02-04-0559","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1002\/ijc.26129","article-title":"Reference ranges for HE4 and CA125 in a large Asian population by automated assays and diagnostic performances for ovarian cancer","volume":"130","author":"Park","year":"2012","journal-title":"Int J Cancer"},{"key":"key20180107150713_b32-mco-02-04-0559","first-page":"931","article-title":"The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy","volume":"43","author":"Dong","year":"2008","journal-title":"Chin J Obstet Gynecol"},{"key":"key20180107150713_b33-mco-02-04-0559","first-page":"25","article-title":"Significance of using combined assays of serum human epididymis secretory protein 4, CA125 and ROMA in the diagnosis of ovarian malignancy and pelvic mass","volume":"5","author":"Wu","year":"2012","journal-title":"J Basic Clin Oncol"},{"key":"key20180107150713_b34-mco-02-04-0559","first-page":"4","article-title":"The differential diagnostic value of HE4, CA125 and the risk of ovarian malignancy aligorithm in ovarian tumor","volume":"30","author":"Yang","year":"2010","journal-title":"Suzhou Univ J Med Sci"},{"key":"key20180107150713_b35-mco-02-04-0559","first-page":"443","article-title":"The clinical value of HE4 and CA125 combined with sB7-H4 in early diagnosis of ovarian cancer","volume":"17","author":"Huang","year":"2011","journal-title":"Hebei Med"},{"key":"key20180107150713_b36-mco-02-04-0559","first-page":"2","article-title":"Clinical application of combined HE4 and CA125 differentiate malignant ovarian tumors from ovarian endometriotic cysts","volume":"21","author":"Li","year":"2013","journal-title":"Mod Oncol"},{"key":"key20180107150713_b37-mco-02-04-0559","first-page":"119","article-title":"Combined detection of serum CA125 and human epididymis protein 4 levels in ovarian cancer","volume":"28","author":"Liu","year":"2010","journal-title":"Chin J Clin Lab Sci"},{"key":"key20180107150713_b38-mco-02-04-0559","first-page":"14","article-title":"Changes and clinical significance of serum HE4 in patients with ovarian cancer","volume":"26","author":"Jiang","year":"2010","journal-title":"J Pract Med"},{"key":"key20180107150713_b39-mco-02-04-0559","first-page":"6","article-title":"Diagnostic value of combined measurement of CA125, HE4 and imaging examination patients with epithelial ovarian cancer","volume":"33","author":"Jing","year":"2011","journal-title":"J Third Mil Med Univ"},{"key":"key20180107150713_b40-mco-02-04-0559","first-page":"3","article-title":"Clinical significance of detecting serum HE4, CA125 and CA724 levels in diagnoses of ovarian malignancies","volume":"19","author":"Yao","year":"2012","journal-title":"Labeled Immunoassays Clin Med"},{"key":"key20180107150713_b41-mco-02-04-0559","first-page":"4","article-title":"The diagnostic values of combined determination of serum tumor markers HE4, TPS and CA125 levels in patients with ovarian cancer","volume":"23","author":"Yao","year":"2010","journal-title":"J Radioimmunol"},{"key":"key20180107150713_b42-mco-02-04-0559","first-page":"1139","article-title":"Studies on value of combination of human epididymis protein 4 and CA125 in patients with ovarian cancer","volume":"20","author":"Wang","year":"2010","journal-title":"Chin J Health Lab Technol"},{"key":"key20180107150713_b43-mco-02-04-0559","first-page":"219","article-title":"Clinic value of HE4, CA125 combined with risk of ovarian malignancy algorithm (ROMA) in the diagnosis for ovarian cancer","volume":"19","author":"Li","year":"2013","journal-title":"J Chin Oncol"},{"key":"key20180107150713_b44-mco-02-04-0559","first-page":"5","article-title":"Serum HE4 and CA125 in the diagnosis of ovarian cancer","volume":"10","author":"Ke","year":"2010","journal-title":"Mod Hosp"},{"key":"key20180107150713_b45-mco-02-04-0559","first-page":"1","article-title":"Significance of HE4 detection for diagnosis of ovarian cancer as compared with CA125 in 69 cases","volume":"33","author":"Lin","year":"2013","journal-title":"Curr Immun"},{"key":"key20180107150713_b46-mco-02-04-0559","doi-asserted-by":"crossref","first-page":"4159","DOI":"10.1200\/JCO.2007.11.9594","article-title":"How do you distinguish a malignant pelvic mass from a benign pelvic mass? Imaging, biomarkers, or none of the above","volume":"25","author":"Moore","year":"2007","journal-title":"J Clin Oncol"},{"key":"key20180107150713_b47-mco-02-04-0559","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ejogrb.2012.10.036","article-title":"Human epididymis protein 4 for differential diagnosis between benign gynecologic disease and ovarian cancer: a systematic review and meta-analysis","volume":"167","author":"Lin","year":"2013","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"key20180107150713_b48-mco-02-04-0559","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1515\/cclm-2011-0477","article-title":"Diagnostic value of HE4 for ovarian cancer: a meta-analysis","volume":"50","author":"Yu","year":"2012","journal-title":"Clin Chem Lab Med"}],"container-title":["Molecular and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/mco.2014.279\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,7]],"date-time":"2018-01-07T10:07:32Z","timestamp":1515319652000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/mco.2014.279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,16]]},"references-count":48,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2014,4,16]]},"published-print":{"date-parts":[[2014,7]]}},"alternative-id":["10.3892\/mco.2014.279"],"URL":"https:\/\/doi.org\/10.3892\/mco.2014.279","relation":{},"ISSN":["2049-9450","2049-9469"],"issn-type":[{"value":"2049-9450","type":"print"},{"value":"2049-9469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,16]]}}}